Relative to the tumor quality of the model group, the low-dose LBP, high-dose LBP, LBP + CXCLIO, and CTX medication groups all showed a certain tumor inhibition trend, and the inhibition rates were 37.83%, 12.50%, 16.11%, and 59.20%, respectively. This evidence concerns the gene LBP and neoplasm.